U.S. Markets closed

Ex-Dividend Alert: Sabra Health Care REIT Has a Dividend Yield of 10.80%; Will Trade Ex-Dividend on February 14, 2017

LONDON, UK / ACCESSWIRE / February 13, 2018 / Active-Investors has a free review on Sabra Health Care REIT, Inc. (NASDAQ: SBRA) following the Company's announcement that it will begin trading ex-dividend on February 14, 2018. In order to capture the dividend payout, investors must purchase the stock a day prior to the ex-dividend date that is by latest at the end of the trading session on February 13, 2018. Active-Investors has initiated due-diligence on this dividend stock. Register with us for more free research including the one on SBRA:


If your portfolio includes dividend stocks, you have come to the right place for timely information. All you need to do is sign up for your free membership at:


Dividend Declared

On February 05, 2018, Sabra's Board of Directors declared a quarterly cash dividend of $0.45 per share of common stock. The dividend will be paid on February 28, 2018, to common stockholders of record as of the close of business on February 15, 2018.

In addition, on February 05, 2018, Sabra's Board declared a quarterly cash dividend of $0.4453125 per share of Series A Preferred Stock. The dividend will be paid on February 28, 2018, to preferred stockholders of record as of the close of business on February 15, 2018.

Sabra's indicated dividend represents a yield of 10.80%, which is more than double compared to the average dividend yield of 5.25% for the financial sector. The Company has raised dividend for seven consecutive years.

Dividend Insights

Sabra has a dividend pay-out ratio of 72.9%, which denotes that the Company distributes approximately $0.73 for every $1.00 earned. The dividend payout ratio reflects how much amount a company is returning to shareholders versus how much money it is keeping on hand to reinvest in growth, to pay off debt, and/or to add to its cash reserves.

According to analysts' estimates, Sabra is forecasted to report earnings of $1.83 per share for the next year compared to the Company's annualized dividend of $1.80 per share. One of the primary reasons for the difference between earnings and annualized dividend is that Sabra is a Real Estate Investment Trust (REIT) which is structured by law to distribute at least 90% of earnings. Moreover, since REITs generate income from owning portfolios of investment real estate, they are likely to have higher depreciation charges.

Since depreciation is a non-cash charge, it does not directly impact the ability of dividend the companies can distribute. For this reason, Fund from Operations (FFO) is calculated by adding depreciation and amortization to earnings and subtracting any gains on sales which then provides a better picture of any company's profitability and capacity to pay and to sustain dividends. For instance, for the quarter ended September 30, 2017, Sabra's net income attributable to common stockholders was $12.53 million, or $0.11 per diluted share, compared to $22.78 million, or $0.35 per diluted share, in Q3 2016.

On the other hand, Sabra's Q3 2017, Normalized FFO attributable to common stockholders was $70.30 million, or 0.63 per diluted share, compared to $35.45 million, or $0.54 per diluted share, in Q3 2016. The Company's strong financial position indicates its ability to absorb any fluctuations in earnings and cash flow and to sustain the dividend distribution for a long period.

Upcoming Earnings

On February 05, 2018, Sabra announced that it will issue its fourth quarter (Q4) 2017 earnings results on February 21, 2018. A conference call with a simultaneous webcast to discuss the Q4 2017 results will be held on February 22, 2018, at 10:00 a.m. Pacific Time.

About Sabra Health Care REIT, Inc.

Sabra, a Maryland corporation, operates as a self-administered, self-managed REIT that, through its subsidiaries, owns and invests in real estate serving the healthcare industry throughout the United States and Canada. As of September 30, 2017, Sabra's real estate properties held for investment included 55,904 beds/units, spread across the United States and Canada.

Stock Performance Snapshot

February 12, 2018 - At Monday's closing bell, Sabra's stock slightly advanced 0.90%, ending the trading session at $16.81.

Volume traded for the day: 3.45 million shares, which was above the 3-month average volume of 1.68 million shares.

After yesterday's close, Sabra's market cap was at $2.95 billion.

Price to Earnings (P/E) ratio was at 21.61.

The stock has a dividend yield of 10.71%.

The stock is part of the Financial sector, categorized under the REIT - Healthcare Facilities industry. This sector was up 1.1% at the end of the session.


Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.


A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visithttp://active-investors.com/legal-disclaimer/.


For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com

Phone number: 73 29 92 6381

Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors